Expression of cyclooxygenase-2 in canine nasal carcinomas.
Cyclooxygenase(COX)-2 expression was evaluated in 24 paraffin-embedded canine nasal carcinoma tissue samples by immunohistochemistry. Several different tumor types were represented, including carcinomas, adenocarcinomas and squamous cell carcinomas. COX-2 expression was identified in 17/24 cases (71%). The proportion of positive cells expressing COX-2 ranged from 10 to 95% and COX-2 expression was predominantly localized in the cytoplasm. Treatment with a COX-2 inhibitor should be investigated, along with the utilization of COX-2 expression as a prognostic marker.
Impellizeri
Joseph A
JA
Veterinary Oncology Services, PLLC, 69 Dakota Drive, Hopewell Junction, NY 12533, USA. oncologyvet@yahoo.com
Esplin
D Glen
DG
D000818:Animals; D014408:Biomarkers, Tumor; D002277:Carcinoma / Q000188:drug therapy / Q000201:enzymology / Q000662:veterinary*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy / Q000201:enzymology*; D004285:Dogs; D005260:Female; D007150:Immunohistochemistry / Q000662:veterinary; D008297:Male; D009669:Nose Neoplasms / Q000201:enzymology / Q000662:veterinary*
D014408:Biomarkers, Tumor; D052246:Cyclooxygenase 2 Inhibitors; D051546:Cyclooxygenase 2